Abstract
The ability to demonstrate tumour foci that are undetected by conventional imaging has resulted in the emergence of positron emission tomography (PET) as a valuable clinical tool in oncology. This article describes the technique and indications for fluorine-18 labelled fluorodeoxyglucose (18FDG)-PET in lung cancer, demonstrating the high accuracy and cost-effectiveness of 18FDG-PET in the characterisation of solitary pulmonary nodules and in the pre-operative staging of non-small cell lung cancer. Emerging roles in determination of prognosis, radiotherapy planning, therapy monitoring and diagnosis of recurrence are illustrated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
